报告人：况阳（亚利桑那州立大学）
报告时间：2026年5月29日（周五）上午10:00 - 11:00
报告地点：国交二号楼315会议室
报告摘要：Immune checkpoint inhibitors (ICIs) are a novel cancer therapy that may induce tumor regression across multiple types of cancer. There has recently been interest in combining the ICIs with other forms of treatments, as not all patients benefit from monotherapy. We propose a mathematical model consisting of ordinary differential equations to investigate the combination treatments of the ICI avelumab and the immunostimulant NHS-muIL12. We validated the model using the average tumor volume curves provided in Xu et al. (2017). This mathematical model produce insightful conditions for local stability for both the tumorous and tumor-free steady states. Additionally, we conducted systematic mathematical analysis for the case that both drugs are applied continuously. Numerical simulations suggest that the two drugs act synergistically. Compared to monotherapy, about one-third the dose of both drugs is required in combination for tumor control.
专家简介: 况阳教授自1988年起担任亚利桑那州立大学（ASU）数学教授。于1984年获得中国科学技术大学理学学士学位，1988年在阿尔伯塔大学获得数学博士学位。发表了200余篇论文及16部专著（包括11期特刊），并创立和主编了《Mathematical Biosciences and Engineering》期刊。曾指导28篇关于数学与计算生物学的博士论文，并在美国主持了多项重要的跨学科研究项目。致力于发展时滞微分方程模型的实用理论，以及结合生物和医学资源质量的模型。近期研究重点在于构建并验证科学合理、计算可行的数学模型，用以描述宿主体内各类疾病及其治疗的复杂动力学过程。
